Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats

Brain Research Bulletin

Volumn 86, Issue 1-2, 2011, Pages 36-41

  Sugata, Sei ^a   Hanaya, Ryosuke ^a   Kumafuji, Kenta ^b   Tokudome, Mai ^a   Serikawa, Tadao ^b   Kurisu, Kaoru ^c   Arita, Kazunori ^a   Sasa, Masashi ^d  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d Nagisa Clinic   (Japan)

Author keywords

Brain derived neurotrophic factor (BDNF); Hippocampal cell loss; Levetiracetam; Mossy fiber sprouting; Neuroprotection; Spontaneous epileptic rat (SER)

Indexed keywords

ATAXIN 3; BRAIN DERIVED NEUROTROPHIC FACTOR; ETIRACETAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DENTATE GYRUS; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HIPPOCAMPAL SCLEROSIS; HIPPOCAMPUS; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; HIPPOCAMPUS; NEURONS; NEUROPROTECTIVE AGENTS; PIRACETAM; PLACEBOS; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; SCLEROSIS; SEIZURES;

EID: 80051581727     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.05.017     Document Type: Article

References (48)

1. Amano T., Amano H., Matsubayashi H., Ishihara K., Serikawa T., Sasa M. Enhanced Ca(2+) influx with mossy fiber stimulation in hippocampal CA3 neurons of spontaneously epileptic rats. Brain Res. 2001, 910:199-203.
2. Armijo J.A., Shushtarian M., Valdizan E.M., Cuadrado A., de las Cuevas I., Adín J. Ion channels and epilepsy. Curr. Pharm. Des. 2005, 11:1975-2003.
3. Cavazos J.E., Das I., Sutula T.P. Neuronal loss induced in limbic pathways by kindling: evidence for induction of hippocampal sclerosis by repeated brief seizures. J. Neurosci. 1994, 14:3106-3121.
4. Czapinski P., Blaszczyk B., Czuczwar S.J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5:3-14.
5. Errington A.C., Stohr T., Lees G. Voltage gated ion channels: target for anticonvulsant drugs. Curr. Top. Med. Chem. 2005, 5:15-30.
6. Genton P., Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord. 2000, 2:99-105.
7. Gower A.J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995, 22:207-213.
8. Hanaya R., Sasa M., Ujihara H., Ishihara K., Serikawa T., Iida K., Akimitsu T., Arita K., Kurisu K. Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res. 1998, 789:274-282.
9. Hanaya R., Kiura Y., Kurisu K., Sakai N., Serikawa T., Sasa M. N-acetyl-l-aspartate activates hippocampal CA3 neurons in rodent slice preparations. Brain Res. Bull. 2008, 75:663-667.
10. Hanaya R., Sasa M., Sugata S., Tokudome M., Serikawa T., Kurisu K., Arita K. Hippocampal cell loss and propagation of abnormal discharges accompanied with the expression of tonic convulsion in the spontaneously epileptic rat. Brain Res. 2010, 1328:171-180.
11. Hanon E., Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001, 10:287-293.
12. Ishihara K., Sasa M., Momiyama T., Ujihara H., Nakamura J., Serikawa T., Yamada J., Takaori S. Abnormal excitability of hippocampal CA3 pyramidal neurons of spontaneously epileptic rats (SER), a double mutant. Exp. Neurol. 1993, 119:287-290.
13. Ishimaru Y., Chiba S., Serikawa T., Sasa M., Inaba H., Tamura Y., Ishimoto T., Takasaki H., Sakamoto K., Yamaguchi K. Effects of levetiracetam on hippocampal kindling in Noda epileptic rats. Brain Res. 2010, 1309:104-109.
14. Ji-qun C., Ishihara K., Nagayama T., Serikawa T., Sasa M. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Epilepsia 2005, 46:1362-1370.
15. Johannessen S.I., Battino D., Berry D.J., Bialer M., Kramer G., Tomson T., Patsalos P.N. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 2003, 25:347-363.
16. Kaminski R.M., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., Matagne A., Klitgaard H. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009, 50:1729-1740.
17. Kasteleijn-Nolst Trenité D.G., Hirsc E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord. Suppl. 2003, 1:39-44.
18. Kitada K., Akimitsu T., Shigematsu Y., Kondo A., Maihara T., Yokoi N., Kuramoto T., Sasa M., Serikawa T. Accumulation of N-acetyl-l-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J. Neurochem. 2000, 74:2512-2519.
19. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
20. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 2001, 42(Suppl. 4):13-18.
21. Knipper M., Leung L.S., Zhao D., Rylett R.J. Short-term modulation of glutamatergic in adult rat hippocampus by NGF. Neuroreport 1994, 5:2433-2436.
22. Koyama R., Yamada M.K., Fujisawa S., Katoh-Semba R., Matsuki N., Ikegaya Y. Brain-derived neurotrophic factor induces hyperexcitable reentrant circuits in the dentate gyrus. J. Neurosci. 2004, 24:7215-7224.
23. Kuramoto T., Kitada K., Inui T., Sasaki Y., Ito K., Hase T., Kawagachi S., Ogawa Y., Nakao K., Barsh G.S., Nagao M., Ushijima T., Serikawa T. Attractin/mahogany/zitter plays a critical role in myelination of the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:559-564.
24. Leppik I., Morrell M., Godfroid P., Arrigo C. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia 2003, 44:1232-1350.
25. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002, 50:105-123.
26. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. 1993, 232:147-158.
27. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
28. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9861-9866.
29. Margineanu D.G., Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur. J. Pharmacol. 2003, 466:255-261.
30. Marini H., Costa C., Passaniti M., Esposito M., Campo G.M., Ientile R., Adamo E.B., Marini R., Calabresi P., Altavilla D., Minutoli L., Pisani F., Squadrito F. Levetiracetam protects against kainic acid-induced toxicity. Life Sci. 2004, 74:1253-1264.
31. Mhyre T.R., Applegate C.D. Persistent regional increases in brain-derived neurotrophic factor in the flurothyl model of epileptogenesis are dependent upon the kindling status of the animal. Neuroscience 2003, 121:1031-1045.
32. Ohno Y., Ishihara S., Terada R., Serikawa T., Sasa M. Antiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model. Epilepsy Res. 2010, 89:360-364.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1996, Academic Press, San Diego. 3rd ed.
34. Pitman A., Sutula T.P. Is epilepsy a progressive disorder? Process for new therapeutic approaches in temporal lobe epilepsy. Lancet Neurol. 2002, 1:173-181.
35. Represa A., Le Gall La Salle G., Ben-Ari Y. Hippocampal plasticity in the kindling model of epilepsy in rats. Neurosci. Lett. 1989, 99:345-350.
36. Rhem S., Mehraein P., Anzil A.P., Deerberg F. A new rat mutant with detective overhairs and spongy degeneration of the central nervus system: clinical pathological studies. Lab. Animal Sci. 1982, 32:70-73.
37. Sasa M., Ohno Y., Ujihara H., Fujita Y., Yoshimura M., Takaori S., Serikawa T., Yamada J. Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. Epilepsia 1988, 29:505-513.
38. Sasa M. A frontier in epilepsy: novel antiepileptogenetic drugs. J. Pharmacol. Sci. 2006, 100:487-494.
39. Serikawa T., Yamada J. Epileptic seizures in rats homozygous for two mutations, zitter and tremor. J. Hered. 1986, 77:441-444.
40. Serikawa T., Yamada J., Ujihara H., Ohno Y., Sasa M., Takaori S. Ontogeny of absence-like and tonic seizures in the spontaneously epileptic rat. Lab. Anim. 1991, 25:216-221.
41. Tokuda S., Sofue N., Ohno Y., Sasa M., Serikawa T. Inhibitory effects of levetiracetam on absence seizures in a novel absence-like epilepsy animal model, Groggy rat. Brain Res. 2010, 1359:298-303.
42. Vinogradova L.V., van Rijn C.M. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia 2008, 49:1160-1168.
43. Wang H., Gao J., Lassiter T.F., McDonagh D.L., Sheng H., Warner D.S., Lynch J.R., Laskowitz D.T. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit. Care 2006, 5:71-78.
44. Yamada J., Serikawa T., Ishiko J., Inui T., Takada H., Kawai Y., Okaniwa A. Rats with congenital tremor and curled whisker and hair. Exp. Anim. 1985, 34:183-188.
45. Yan H.D., Ji-qun C., Ishihara K., Nagayama T., Serikawa T., Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 2005, 46:1170-1177.
46. Yan H.D., Ishihara K., Hanaya R., Kurisu K., Serikawa T., Sasa M. Voltage-dependent calcium channel abnormalities in hippocampal CA3 neurons of spontaneously epileptic rats. Epilepsia 2007, 48:758-764.
47. Yilmazer-Hanke D.M., Wolf H.K., Scgeamm J., Elger C.E., Wiestler O.D., Blumcke I. Subregional pathology of the amygdale complex and entorhinal region in surgical specimen from patients with pharmacoresistant temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 2000, 59:907-920.
48. Zona C., Niespodziany I., Marchetti C., Klitgaard H., Bernardi G., Margineanu D.G. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001, 10:279-286.